21 Enhancer reactivation and pluripotency gene (PpG) expression were recently shown to induce 22 stemness and enhance tumorigenicity in cancer stem cells. Silencing of PpG enhancers during 23 embryonic stem cell differentiation involves changes in chromatin state, facilitated by the activity 24 of Lsd1/Mi2-NuRD-Dnmt3a complex. In this study, we observed a widespread retention of 25 H3K4me1 at PpG enhancers and partial repression of PpGs in F9 embryonal carcinoma cells 26 (ECCs) post differentiation. Absence of H3K4me1 demethylation could not be rescued by Lsd1 27 overexpression. Based on the observation that H3K4me1 demethylation is accompanied by 28 strong Oct4 repression in P19 ECCs, we tested if Lsd1-Oct4 interaction modulates Lsd1 activity. 29 Our data show a dose dependent inhibition of Lsd1 by Oct4 in vitro and retention of H3K4me1 30 at PpG enhancers post differentiation in Oct4 overexpressing P19 ECCs. These data reinforce 31
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Enhancer reactivation and pluripotency gene (PpG) expression were recently shown to induce 22 stemness and enhance tumorigenicity in cancer stem cells. Silencing of PpG enhancers during 23 embryonic stem cell differentiation involves changes in chromatin state, facilitated by the activity 24 of Lsd1/Mi2-NuRD-Dnmt3a complex. In this study, we observed a widespread retention of 25 H3K4me1 at PpG enhancers and partial repression of PpGs in F9 embryonal carcinoma cells 26 (ECCs) post differentiation. Absence of H3K4me1 demethylation could not be rescued by Lsd1 27 overexpression. Based on the observation that H3K4me1 demethylation is accompanied by 28 strong Oct4 repression in P19 ECCs, we tested if Lsd1-Oct4 interaction modulates Lsd1 activity. 29
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at PpG enhancers post differentiation in Oct4 overexpressing P19 ECCs. These data reinforce 31
Introduction 36
Cell type specific gene expression is regulated by chromatin conformation which facilitates the 37 interaction of distally placed enhancer elements with the specific gene promoter (Banerji et al., 38 1981 , Bulger and Groudine, 2011 , Ong and Corces, 2011 , Plank and Dean, 2014 . Enhancers 39 house majority of transcription factor binding sites and amplify basal transcription thus playing a 40 critical role in signal dependent transcriptional responses (summarized in (Heinz et al., 2015) ). Petell et al., 2016) . In response to the differentiation signal, the 53 coactivator complex (Oct4, Sox2, Nanog and Mediator complex) dissociates from the enhancer 54 followed by the activation of pre-bound Lsd1-Mi2/NuRD enzymes. The histone demethylase, 55
Lsd1, demethylates H3K4me1, and HDAC in NuRD complex deacetylates the H3K27Ac (Whyte 56 et al., 2012) . Our previous studies have shown that the histone demethylation event is critical for 57 the activation of DNA methyltransferase Dnmt3a, which interacts with the demethylated histone 58 H3 tails through its chromatin-interacting ADD (ATRX-Dnmt3a-Dnmt3L) domain allowing site-59 specific methylation at pluripotency gene enhancers (PpGe) (Petell et al., 2016) . These studies 60 also suggest that an aberrant inhibition of Lsd1 activity could cause a failure to gain DNA 61 methylation leading to incomplete repression of PpGs. 62
Several studies have reported on potential mechanisms that control site specific targeting and 63 catalytic activity of Lsd1. It was shown that whereas the interaction with CoREST activates the 64 enzyme, BHC80 inhibits Lsd1 demethylation activity (Shi et al., 2005) . The substrate specificity 65 of Lsd1 is regulated by its interaction with androgen receptor and estrogen related receptor α, or 66 by alternative splicing which add four or eight amino acids to the Lsd1 enzyme (Carnesecchi et the active site of Lsd1 by mimicking histone H3 tail and could potentially inhibit its activity (Baron 71 et al., 2011) . Interaction of p53 C' terminal domain with Lsd1 active site inhibits its enzymatic 72 activity (Speranzini et al., 2017) . Lsd1 was also shown to be present in the Oct4 interaction 73 network, and therefore could be targeted to Oct4 bound regulatory elements which largely control 74 pluripotency and stemness (Pardo et al., 2010 , van den Berg et al., 2010 . understand the mechanism by which cancer cells retain PpG expression, we investigated the 89 mechanism of enhancer-mediated regulation of PpG expression in ECCs. Our data showed in 90 differentiating F9 ECCs, that the PpGs are partially repressed. This was concomitant with H3K27 91 deacetylation but an absence of Lsd1-mediated H3K4me1 demethylation at PpGe. Presence of 92
H3K4me1 prevented Dnmt3a from methylating the DNA at these sites potentially abrogating 93
PpGe silencing. Drug-mediated inhibition as well as overexpression of Lsd1 had little or no effect 94 on enhancer silencing and PpG repression confirming a loss of Lsd1 dependence. Given that 95
Oct4 was expressed at substantial levels in F9 ECCs post differentiation, we investigated the 96 effect of Lsd1-Oct4 interaction on Lsd1 catalytic activity. Using in vitro histone demethylation 97 assays, we discovered that Lsd1-Oct4 interaction inhibits the Lsd1 activity potentially causing 98 retention of H3K4me1 at PpGe in F9 ECCs. We tested this prediction in P19 ECCs in which we 99 observed H3K4me1 demethylation at PpGe accompanied by loss of Oct4 expression post 100 differentiation. Overexpression of Oct4 in differentiating P19 ECCs led to retention of H3K4me1 101 at PpGe confirming the role of Oct4-mediated Lsd1 inhibition at these sites. Taken together our 102 data show that inhibition of Lsd1 activity and Dnmt3a leads to the establishment of a "primed" 103 enhancer state, which is open for coactivator binding and prone to reactivation. We speculate that 104 aberrant expression of Oct4 in CSCs facilitates the establishment of "primed" enhancers, 105 reactivation of which support tumorigenicity. 106
Results: 107

PpGs are partially repressed in differentiating F9 ECCs 108
ECCs share many characteristics with ESCs including mechanisms governing regulation of 109 gene expression and differentiation (Alonso et al., 1991) . Based on the observation that 110 aberrant PpG expression is commonly found in cancers , we 111 compared the magnitude of PpG repression in F9 ECCs with that in ESCs pre-and post-112 differentiation. F9 ECCs and ESCs were induced to differentiate with retinoic acid (RA) and 113 expression of eight PpGs at 4 and 8 days (D4 and D8) post induction was measured by RT-114 qPCR. The data show that in differentiating F9 ECCs, several PpGs were incompletely 115 repressed, of which the pioneer factors Oct4 and Nanog showed only 50% loss of expression at 116 D8 post differentiation. Comparatively in ESCs, the expression of most PpGs was reduced by 117 more than 80% at D4 post differentiation ( Figures 1A and 1B ). The expression of Sox2 and 118
Trim28 was maintained post differentiation as an anticipated response to RA signaling guiding 119
ESCs towards neural lineage. A substantial increase in the expression of Lefty1 and Lefty2 120 genes in F9 ECCs suggests potential activation of germ cell and testis development program 121 (Zhu et al., 2013) . Continued expression of PpGs in F9 ECCs was also evident by positive 122 alkaline phosphatase staining and SSEA-1 immunofluorescence in differentiating F9 ECCs that 123 is completely lost in ESCs post differentiation ( Figures 1C and 1D) . We asked if failure to exit 124 pluripotency in F9 ECCs was caused by an inability to activate lineage-specific genes. Our data 125 showed 10-50 fold increase in expression of the lineage specific genes Gata4, FoxA2, Olig2, 126
Gata6, Cxcr4 and Fgf5 ( Figure 1E ), endorsing a standard response to signal of differentiation. 127
Given that previous studies in ESCs have established a critical role of enhancer silencing in 128 complete PpG repression, we next investigated if PpGe were fully decommissioned in F9 ECCs 129 post differentiation**. 130
DNA methylation is not established at PpGe during F9 ECC differentiation 131
We have previously reported that in differentiating ESCs, PpGe decommissioning involves gain 132 of DNA methylation, which is required for complete PpG repression. (Petell et al., 2016) . We where DNA methylation was partially lost post differentiation ( Figure S1B ). This is consistent 139 with the observed partial repression of most PpGs and an induction of Lefty2 expression in 140 these cells ( Figure 1A) . 141
We confirmed that absence of DNA methylation at PpGe was not due to the low expression of Figure 2E ). To determine the function of genes 169 associated with NCDM PpGe, we performed Ingenuity pathway analysis (IPA) 170 (www.qiagen.com/ingenuity), which showed a significant enrichment of Oct4 and Nanog 171 regulated mammalian embryonic stem cell and molecular mechanisms of cancer pathways 172 ( Figure 2F ). 173
Given that DNA methylation by Dnmt3a at PpGe requires H3K27 deacetylation and H3K4 174 demethylation by Lsd1/Mi2NurD complex (Whyte et al., 2012) , we anticipate a potential 175 impediment in this process causing a widespread failure to acquire DNA methylation at PpGe. 176
A "primed" PpGe state is established during F9 ECC differentiation 177
We asked if the chromatin state at PpGe in F9 ECCs is impermissible to DNA methylation. 178 ECCs and ESCs at four tested enhancers ( Figure 3C ).These data suggest that retention of 200 H3K4me1 at PpGe is caused by lack of Lsd1 activity in F9 ECCs post differentiation. 201
To confirm the above conclusion we next tested the effect of Lsd1 overexpression or inhibition on 202
PpGe silencing and PpG repression in differentiating F9 ECCs. F9 ECCs were transfected with 203 FLAG-Lsd1 overexpressing plasmid and differentiated at 24 hrs post transfection ( Figure S4A ). 204
We observed no change in H3K4me1 at PpGs post differentiation, rather a small increase at some 205 enhancers, indicating an inhibitory mechanism which affects Lsd1 irrespective of its origin ( confirming the partial activity of Lsd1 at these sites ( Figure 3E ). To test if Lsd1 activity 218 contributed to the generation of H3K4me1 in undifferentiated state, we transiently 219 overexpressed Lsd1 in F9 ECCs and allowed cells to grow for 72 hrs. ChIP-qPCR analysis 220 showed no increase in H3K4me1 levels in Lsd1 overexpressing cells ( Figure S4F ). This 221 suggests that similar to ESCs the deposition of H3K4me1 in the undifferentiated F9 ECCs is 222 largely accomplished by MLL3/4 histone methyltransferases and Lsd1 activity at these sites is 223 Figure S5A ). We analyzed the distribution of H3K4me1 peaks at the regulatory elements 235 across the genome ( Figure S5B ). For further analysis, we identified 1425 H3K4me1 peaks 236 found within 1kb of PpGe previously annotated in ESCs (Whyte et al., 2012). The difference in 237 peak enrichment (i.e. log2FoldChange) between differentiated and undifferentiated was 238 calculated to score for change in H3K4me1 post differentiation. The data showed no change, 239 increase, and decrease in 733, 510, and 182 PpGe respectively. Therefore 87% of PpGe 240 showed no significant decrease in H3K4me1 (no decrease in histone methylation; NDHM PpGe) 241 ( Figure 4A ). We next computed correlation between the three PpGe sub-groups and the 1792 242
PpGe that undergo H3K4me1 demethylation in differentiating ESCs (Whyte et al., 2012) . The 243 data showed that a significant fraction of NDHM PpGe, which exhibit an increase (74%) or no 244 change (69%) in H3K4me1 in F9 ECCs overlap with PpGe that are H3K4me1 demethylated in 245
ESCs (Figures 4B, 4C , and S5C). These observations strongly support our previous conclusion 246 that in F9 ECCs, Lsd1 activity is inhibited leading to retention of H3K4me1 at PpGe. IPA of 247 NDHM PpGe -associated genes showed highest enrichment for Oct4-regulated and stem cell 248 pathways. Comparatively, genes associated with PpGe, which undergo H3K4me1 249 demethylation show enrichment for signaling pathways (Figures 4D and S5D ). A correlation 250 between NCDM and NCHM PpGe, showed that 65% of NDHM PpGe fail to acquire DNA 251 methylation underpinning the role of histone demethylation in the regulation of DNA methylation 252 at PpGe ( Figure 4E ) (Petell et al., 2016) . 253
Lsd1 activity at PpGe is inhibited by its interaction with Oct4 254
Next, we sought to determine the mechanism that inhibits Lsd1 activity. Due to its continued 255 expression in F9 ECCs post differentiation, we assumed that Oct4 remains associated with 256
PpGe and prevents demethylation of H3K4me1. We tested this hypothesis in P19 ECCs in 257 which Oct4 expression was reported to be strongly repressed post differentiation (Li et al., 258 2007 ). After confirming a 90% reduction in Oct4 expression ( Figure 5A ), we probed H3K4me1 259 demethylation at PpGe during P19 ECC differentiation. Indeed, our data show decreased 260 enrichment of H3K4me1 at PpGe 4 days post differentiation ( Figure 5B ). Similar to ESCs, we 261 also observed a massive cell death when P19 ECCs were exposed to Lsd1 inhibitor during 262 differentiation ( Figure S6A ). The change in the chromatin state was accompanied by 40% gain 263 of DNA methylation at these sites ( Figure 5C ). 264
This observation together with the IPA showing enrichment of Oct4-regulated genes in NCHM 265 and NCDM enhancers, suggested that Oct4 may regulate the demethylase activity of Lsd1 at 266
PpGe. Co-precipitation experiments using recombinant proteins, GST-Lsd1 and Oct4, confirmed 267 a direct interaction between Oct4 and Lsd1 ( Figure 6A ). This is concurrent with previous reports 268 which suggested that Oct4 interacts with Lsd1 and the Mi2/NuRD complex in ESCs (van den 269
Berg et al., 2010, Pardo et al., 2010) . To test the effect of Oct4 interaction on Lsd1 catalytic 270 activity, we performed Lsd1 demethylation assays using H3K4me2 peptide as a substrate. Our 271 data showed that in the presence of Oct4, Lsd1 activity was reduced to by 60-70% in a dose 272 dependent manner. This reduction in activity was not observed in the presence of recombinant 273
Dnmt3a protein ( Figures 6B and 6C) . We also performed Lsd1 demethylation assays using 274 Figure 6D ). These data suggest that in F9 ECCs, due to its continued expression post 279 differentiation, Oct4 remains bound at PpGe and inhibits Lsd1. We tested this prediction directly 280 by stably expressing recombinant Oct4 in P19 ECCs ( Figure S6B ). Following differentiation of 281
Oct4-expressing P19 cells, examination of H3K4me1 showed retention of this mark at PpGe 282 indicating the inhibition of Lsd1 by recombinant Oct4 (Figure 6E ).This was accompanied by a 283 derepression of several PpGs and reduced gain in DNA methylation at their respective 284 enhancers ( Figures 6F and 6G) . Our study here reveals a mechanism by which developmental enhancers could acquire aberrant 318 histone modification and DNA methylation states that affect gene expression. We show in F9 319
ECCs, that compromised activity of histone demethylase, Lsd1, causes retention of H3K4me1 320 and absence of DNA methylation at the PpGe, leading to a primed state of enhancers. Unlike 321 the silenced state, the "primed" enhancer state grants accessibility for coactivator binding which 322 renders cells highly vulnerable to small increase in the expression of oncogenic coactivators or 323 master transcription factors (Zaret and Carroll, 2011, Calo and Wysocka, 2013) . 324
We uniquely discovered that Lsd1 activity is inhibited by its interaction with the pioneer 325 transcription factor Oct4, which is expressed at a substantial level in F9 ECCs post can be fine-tuned by its interaction with numerous factors allowing the enzyme to function in 334 various cellular processes including differentiation and disease. 335
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STAR Methods 485
Cell culture and differentiation: 486 
Chromatin Immunoprecipitation and ChIP-Seq 519
ChIP was performed as described (Petell et al., 2016) . Chromatin was sheared by sonication 520 using Covaris E210 device, according to the manufacturer's protocol. 8µg of sheared 521 crosslinked chromatin was incubated with 8µg of antibody pre-loaded on 1:1 ratio of protein A 522 and protein G magnetic beads (Life Technologies, 10002D and 10004D, respectively). After 523 washing the beads, the samples were eluted in 1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 524 8.0. Crosslinking was reversed by incubation at 65°C for 30 min with shaking. Samples were 525 treated with RNase (Roche, 11119915001) for 2 h at 37°C, and subsequently treated with 526
Proteinase K (Worthington, LS004222) for 2 h at 55°C. DNA was purified by Phenol:Chloroform 527 extraction followed by ethanol precipitation and quantified using PicoGreen (Life Technologies, 528 P11495) and NanoDrop 3300 fluorospectrometer. qPCR was then performed using equal 529 amounts of IN and IP samples. Fold enrichment was calculated as: 2^( C t (IN)-C t (IP)). 530 Supplementary Table S4 lists sequences of primers used. 531
Gene expression analysis 532
RNA was isolated by TRIzol (Invitrogen, 15596026) according to manufacturer's protocol. 533
Samples were treated with DNAse (Roche, 04716728001) at 37°C, and then purified using 534
Quick-RNA TM MiniPrep Plus Kit (ZymoReseach, R1057). Reverse-transcription quantitative PCR 535 was performed by using Verso One-Step RT-qPCR kits (Thermo Scientific, AB-4104A) with 1µg 536 of purified RNA. Gene expression was calculated as ∆C t which is C t (Gene)-C t (Gapdh). Change 537 in gene expression is reported as fold change relative to that in undifferentiated cells, which was 538 set to 1. See Supplementary table S4 for primers used. 539
Microscopy 540
Bright field images of Embryoid bodies (EBs) were obtained with Zeiss microscope at 10X 541 objective. Alkaline phosphatase staining was performed using solutions supplied by an alkaline 542 phosphatase staining kit (Sigma, AB0300). Cells were cross-linked with 1% formaldehyde for 5 543 min, followed by quenching with a final concentration of 150 mM Glycine. Cells were washed 544 twice with 1xPBS, then twice with combined staining solution (BCIP and NBT). The stain was 545 developed in the dark for 5 min, then washed three times with 1x PBS. SSEA-1 546 immunofluorescence was performed using the following antibodies: anti-SSEA-1 (Millipore, 547 MAB430) and AlexaFluor 555 nm (Life Technologies, A21422). SSEA-1 and Alkaline 548 phosphatase staining were imaged using 20X objectives under Nikon Ts and Zeiss 549 microscopes, respectively. 550
Co-precipitation experiment 551
Immunoprecipitation assays were performed with 1µg of GST-Lsd1 (Sigma, SRP0122) 552 incubated with 1µg of recombinant Oct4 (abcam, ab134876) and Glutathione sepharose 4B (GE 553 healthcare, 17-0756-01) resin in binding buffer (50mM Tris pH8.5, 50mM KCl, 5mM MgCl, 0.5% 554 BSA, and 5% glycerol, complemented with a cocktail of protease inhibitors) overnight at 4°C 555 with gentle agitation. The resin was washed twice with binding buffer and proteins were eluted 556 elution buffer (50mM Tris-HCl, 10mM reduced glutathione, pH8) according to manufacturer's 557 instructions. Eluate and input were loaded onto 10% SDS-PAGE gels and blots were probed 558 using anti-Lsd1 (abcam, ab17721) and anti-Oct4 (Santa Cruz, sc-8628) antibodies. 559
In vitro Lsd1 demethylase activity assay 560
In vitro fluorometric assay were performed using Lsd1 demethylase activity assay, Epigenase TM 561 kit (Epigentek, P-0379) according to manufacturer's protocol. 0.25µM of Lsd1 (Sigma, 562 SRP0122) was used together with 0.5µM (or as indicated) of Oct4 (abcam, ab134876 and 563 ab169842) or BSA (Sigma, A3059) or catalytic domain of Dnmt3a (purified in house) or 0.1mM 564 Lsd1 inhibitor Tranylcypromine (TCP). Signals were measured using CLARIOstar plate reader 565 and analyzed using MARs software as described by the manufacturer. 566
Histone demethylation assay 567
Lsd1 histone demethylation assays were performed as described in (Shi et al., 2004) . 30µg of 568 bulk histones (Sigma, H9250) in a histone demethylation buffer (50mM Tris pH8.5, 50mM KCl, 569 5mM MgCl, 0.5% BSA, and 5% glycerol) were incubated with 0.25µM of Lsd1 (Sigma, 570 SRP0122) alone, or increasing concentrations (0.125µM, 0.25µM, 0.5µM, 1µM) of Oct4 (abcam, 571 ab134876 and ab169842), or 0.1µM TCP for 4 hrs at 37°C. Lsd1 activity was monitored by 572
Western blot using anti-H3K4me2 antibody (abcam, ab32356). The membrane was stained by 573 Ponceau S to detect equal loading of the reaction mix. showing very similar levels in these cells. β-Actin is the loading control. 591
(E) Gene expression analysis by RT-qPCR and Western blot confirming recombinant Myc-592
Dnmt3a overexpression in F9 ECCs 24 hrs post differentiation (48 hrs post transfection). The 593
data are normalized to Gapdh control and shown relative to untransfected that is set to 1. β-594
Actin is used as loading control for Western blot. The number of CpGs sites used to compute percent methylation within H19 imprinted region in 657 addition to PpG enhancers, and promoters in bisulfite-sequencing analyses. 658 Table S2 . Number of reads for each enhancer used for Bis-Seq analysis. 659
The total number of reads from Wide-Seq runs that were used for data presented in this study. 660
The number of reads were calculated for each sample, enhancer, along with the overall total 661 reads. 662 Table S3 . Number of reads for promoters and imprinted region used for Bis-Seq analysis. 663
The total number of reads from Wide-Seq runs that were used in this study. The number of 664 reads were calculated for each sample, promoter site, imprinted locus as well as the overall total 665 reads. 666 Table S4 . Primers used in this study. 667
A list of all PCR primers used in this study (5' to 3'), separated by technique. The presence of 668 (AminoC6) modification at 3' end of the antisense oligonucleotide of each adaptor is used to 669 block extension. 670
